Morgan Stanley Synaptogenix, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$0.16 - $0.3 $365 - $686	2,287 New	2,287 $0
Q4 2023 Aug 16, 2024	BUY	$0.23 - $0.4 $526 - $914	2,287 New	2,287 $0
Q1 2023 May 15, 2023	BUY	$0.8 - $1.33 $700 - $1,163	875 Added 61.97%	2,287 $1,000
Q4 2022 Feb 14, 2023	SELL	$1.02 - $181.75 $4,285 - $763,531	-4,201 Reduced 74.84%	1,412 $1,000
Q3 2022 Nov 14, 2022	BUY	$4.6 - $172.25 $10,124 - $379,122	2,201 Added 64.51%	5,613 $38,000
Q2 2022 Oct 27, 2022	SELL	$3.88 - $7.41 $23 - $44	-6 Reduced 0.18%	3,412 $17,000
Q2 2022 Aug 15, 2022	SELL	$3.88 - $7.41 $23 - $44	-6 Reduced 0.18%	3,412 $17,000
Q1 2022 Oct 27, 2022	BUY	$6.31 - $10.09 $37 - $60	6 Added 0.18%	3,418 $26,000
Q1 2022 May 13, 2022	SELL	$6.31 - $10.09 $3,514 - $5,620	-557 Reduced 14.01%	3,418 $26,000
Q4 2021 Feb 14, 2022	BUY	$8.38 - $13.72 $32,958 - $53,960	3,933 Added 9364.29%	3,975 $34,000
Q3 2021 Nov 15, 2021	BUY	$6.65 - $12.1 $279 - $508	42 New	42 $0

30K

Ticker SNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,840,630
Market Cap $20.2M
Description
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.